Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene’s PD-1 Approved in China for Tenth Indication, Gastric Cancer

publication date: Feb 24, 2023

Beijing’s BeiGene announced its very successful PD-1 drug, tislelizumab, was approved as a first line therapy for gastric cancer, the tenth indication for the drug in China. In its Q3 financial report, BeiGene said China revenues for tislelizumab were $128 million for the three months, a 62% increase over the year earlier. The company added that it booked $38 million during the quarter from partial recognition of the upfront payments from its out-licensings to Novartis of $650 million for tislelizumab and $300 million for ociperlimab, a TIGIT inhibitor. More details....

Stock Symbols: (NASDAQ: BGNE; HKEX: 06160; SSE: 688235)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital